Compare RLMD & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLMD | GAIN |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | 70 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 752.1M | 653.5M |
| IPO Year | 2012 | N/A |
| Metric | RLMD | GAIN |
|---|---|---|
| Price | $6.93 | $15.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $12.40 | ★ $14.75 |
| AVG Volume (30 Days) | ★ 869.6K | 400.9K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 9.19% |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | $9.07 |
| Revenue Next Year | N/A | $7.32 |
| P/E Ratio | ★ N/A | $4.38 |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.52 | $13.14 |
| 52 Week High | $8.00 | $17.14 |
| Indicator | RLMD | GAIN |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 47.06 |
| Support Level | $6.81 | $15.78 |
| Resistance Level | $7.46 | $17.04 |
| Average True Range (ATR) | 0.42 | 0.61 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 50.17 | 50.71 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.